Pablo Gajate Selected Research

Pablo Gajate Research Topics

Disease

12	Neoplasms (Cancer) 02/2022 - 01/2018
6	Neuroendocrine Tumors (Neuroendocrine Tumor) 11/2021 - 01/2017
3	Fatigue 10/2021 - 10/2019
3	Disease Progression 10/2021 - 01/2020
3	Carcinoma (Carcinomatosis) 01/2021 - 01/2018
3	Primitive Neuroectodermal Tumors (PNET) 01/2020 - 01/2017
1	Prostatic Neoplasms (Prostate Cancer) 02/2022
1	medullary Thyroid cancer 01/2022
1	COVID-19 01/2022
1	Encephalitis (Encephalitis, Rasmussen) 01/2022
1	Delayed Hypersensitivity (Hypersensitivity, Type IV) 01/2022
1	Peripheral Nervous System Diseases (PNS Diseases) 01/2022
1	Hypoxia (Hypoxemia) 11/2021
1	Diarrhea 10/2021
1	Hypertension (High Blood Pressure) 10/2021
1	Brain Neoplasms (Brain Tumor) 01/2021
1	Neuroendocrine Carcinoma 01/2021
1	Lung Neoplasms (Lung Cancer) 01/2021
1	Nausea 01/2021
1	Neoplasm Metastasis (Metastasis) 01/2021
1	Pneumonia (Pneumonitis) 01/2021
1	Melanoma (Melanoma, Malignant) 10/2020
1	Necrosis 10/2020
1	Renal Cell Carcinoma (Grawitz Tumor) 10/2020
1	Insulinoma 11/2019
1	Hypoglycemia (Reactive Hypoglycemia) 11/2019
1	Squamous Cell Carcinoma of Head and Neck 10/2019
1	Squamous Cell Neoplasms (Squamous Cell Cancer) 10/2019
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2019
1	Ovarian Neoplasms (Ovarian Cancer) 01/2019
1	Colorectal Neoplasms (Colorectal Cancer) 12/2012

Drug/Important Bio-Agent (IBA)

2	Monoclonal AntibodiesIBA 01/2021 - 12/2012
2	NivolumabIBA 01/2021 - 10/2020
1	Chimeric Antigen ReceptorsIBA 02/2022
1	Immune Checkpoint InhibitorsIBA 02/2022
1	atezolizumabIBA 01/2022
1	cabozantinibIBA 01/2022
1	mRNA VaccinesIBA 01/2022
1	Capsules (Microcapsules)IBA 01/2022
1	Complement System Proteins (Complement)IBA 01/2022
1	TabletsIBA 01/2022
1	VaccinesIBA 01/2022
1	TH 302IBA 11/2021
1	ProdrugsIBA 11/2021
1	Angiogenesis InhibitorsIBA 11/2021
1	DNA (Deoxyribonucleic Acid)IBA 11/2021
1	Alkylating AgentsIBA 11/2021
1	Sunitinib (Sutent)FDA Link 11/2021
1	isophosphamide mustard (IPAM)IBA 11/2021
1	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 10/2021
1	lenvatinibIBA 10/2021
1	spartalizumabIBA 01/2021
1	Tyrosine Kinase InhibitorsIBA 01/2021
1	Alanine (L-Alanine)FDA Link 01/2021
1	Transaminases (Aminotransferases)IBA 01/2021
1	Aspartic Acid (Aspartate)FDA Link 01/2021
1	osimertinibIBA 01/2021
1	Proteins (Proteins, Gene)FDA Link 01/2021
1	B7-H1 AntigenIBA 01/2021
1	BO-112IBA 10/2020
1	pembrolizumabIBA 10/2020
1	Poly I-CIBA 10/2020
1	palbociclibIBA 01/2020
1	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 11/2019
1	LutetiumIBA 11/2019
1	lutetium Lu 177 dotatateIBA 11/2019
1	Lipase (Acid Lipase)FDA Link 10/2019
1	Messenger RNA (mRNA)IBA 10/2019
1	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 10/2019
1	RogaratinibIBA 10/2019
1	TrabectedinIBA 01/2019
1	PlatinumIBA 01/2019
1	Fluorouracil (Carac)FDA LinkGeneric 01/2018
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2018
1	Temozolomide (Temodar)FDA LinkGeneric 03/2017
1	Capecitabine (Xeloda)FDA Link 03/2017
1	Everolimus FDA Link 01/2017
1	ErbB Receptors (EGF Receptor)IBA 12/2012
1	Cetuximab (Erbitux)FDA Link 12/2012
1	Codon (Codons)IBA 12/2012

Therapy/Procedure

2	Immunotherapy 02/2022 - 01/2022
2	Therapeutics 02/2022 - 10/2021
2	Drug Therapy (Chemotherapy) 01/2018 - 03/2017
1	Castration 02/2022
1	Aftercare (After-Treatment) 10/2021
1	Drug Tapering 10/2021
1	Radiotherapy 01/2021